Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kim Trinkhaus"'
Autor:
Ashley S. Case, Elizabeth K. Nugent, Israel Zighelboim, John T. Hoff, Lorri L. DeWitt, David G. Mutch, Janet S. Rader, L. Stewart Massad, Kim Trinkhaus, Premal H. Thaker
Publikováno v:
Gynecologic Oncology. 116:438-441
The aim of this study was to evaluate the effect of number of chemotherapy cycles and other clinical and pathologic factors on progression-free (PFS) and overall survival (OS) in patients with newly diagnosed cervical cancer.We identified 118 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::697e9b4203b6121d8ed3525396afc02b
https://doi.org/10.1016/j.ygyno.2009.09.045
https://doi.org/10.1016/j.ygyno.2009.09.045
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study
Autor:
C. Fournier, Joan S. James, Kim Trinkhaus, Joel Picus, Kerry J. Williams, Rama Suresh, Benjamin R. Tan
Background Only recently has a standard chemotherapy regimen, gemcitabine plus cisplatin, been established for advanced biliary tract cancers (BTCs) based on a phase III randomized study. The aim of this phase II single-institution trial was to asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6666a71893b62000c82652b5a056291
https://europepmc.org/articles/PMC3028583/
https://europepmc.org/articles/PMC3028583/
Autor:
Katherine B. Chiappinelli, Y. Yin, Premal H. Thaker, Dominic M. Thompson, Nora T. Kizer, L. Ma, Paul J. Goodfellow, Kim Trinkhaus
Publikováno v:
Gynecologic Oncology. 125:S143-S144
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b9b0e1c8e5a4b8bbf1a5f9a4f2f604f
https://doi.org/10.1016/j.ygyno.2011.12.352
https://doi.org/10.1016/j.ygyno.2011.12.352
Autor:
M.A. Powell, Lorri L. DeWitt, Leslie S. Massad, David G. Mutch, Janet S. Rader, Ashley S. Case, Elizabeth K. Nugent, Premal H. Thaker, Israel Zighelboim, Kim Trinkhaus
Publikováno v:
Journal of Clinical Oncology. 27:e16525-e16525
e16525 Background: The standard treatment for locally advanced cervical cancer is combination weekly cisplatin and radiotherapy (RT). Toxicity and compliance issues often result in failure to complete the recommended six cycles of weekly chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a770ad552012d668a72b00cd18aac56
https://doi.org/10.1200/jco.2009.27.15_suppl.e16525
https://doi.org/10.1200/jco.2009.27.15_suppl.e16525
Autor:
James C. Mosley, Amanda F. Cashen, Geoffrey L. Uy, Gregory A. Storch, Linda A. Verkruyse, Kim Trinkhaus, John F. DiPersio, Mark A. Fiala, Ravi Vij, Keith Stockerl-Goldstein, Peter Westervelt, Camille N. Abboud
Publikováno v:
Blood. 112:4340-4340
Background: CMV remains a major cause of morbidity and mortality after aHSCT. The current standard of care for pre-emptive treatment of CMV viremia is IV ganciclovir (GCV). Oral valganciclovir (VGV) has been shown to be effective for the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65c55e2225f8f6813741aa8dcf62df0e
https://doi.org/10.1182/blood.v112.11.4340.4340
https://doi.org/10.1182/blood.v112.11.4340.4340
Autor:
John F. DiPersio, Geoffrey L. Uy, Mark A. Schroeder, Michael P. Rettig, Sandra Lopez, Kim Trinkhaus, Timothy A. Graubert
Publikováno v:
Biology of Blood and Marrow Transplantation. (2):S261
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c00ed6bfc115375fe6b6676cb07f20